- Sartorius will acquire Albumedix Ltd. for approximately £415 million.
- The transaction is expected to close before the end of Q3 2022.
- Albumedix specializes in recombinant albumin-based solutions.
- Recombinant human albumin is crucial for biopharmaceuticals like cell and viral therapies.
Acquisition Details
Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100% of Albumedix Ltd. for approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.
About Albumedix
Albumedix, based in Nottingham, UK, is a leader in recombinant albumin-based solutions. Founded in 1984, the company employs over 100 people and is projected to generate around £33 million in revenue for 2022, with a significant double-digit EBITDA margin.
Strategic Importance
Recombinant human albumin, a key product of Albumedix, is essential for the biopharmaceutical industry. It is used as an animal-free additive in cell culture media and for stabilizing vaccines and viral therapies. This acquisition will bolster Sartorius' advanced therapy solutions, particularly in cell culture media and vaccine production.
Future Plans
Albumedix will be integrated into Sartorius' Bioprocess Solutions Division. The existing 72,000-square-foot site in Nottingham will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials.
Advisors
Milbank LLP provided legal counsel to Sartorius, while William Blair acted as financial advisor to Albumedix. Eversheds Sutherland provided legal counsel to Albumedix.
